1Streilein JW, Bradley D, Sano Y, et al. Immunosuppressive properties of tissues obtained from eyes with experimentally manipulated corneas. Invest Ophthalmol Vis Sci, 1996, 37 (2): 413-424.
2Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci,1996, 37 (12): 2485--2494.
3Aiello L P. Vascular endothelial growth factor. Invest Ophthalmol VisSci, 1997, 38:1647-1652.
4Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol, 1998, 43:245-269.
5Klauber N, Browne F, Anand - Apte B, et al. New activity of spironolactone: inhibition of angiogenesis in vitro and in vivo. Circulation, 1996, 94:2566-2571.
6Arbiser J L, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med, 1998, 4, 376-383.
7Demir T, Celiker U O, Kukner A, et al. Effect of oetreotide on experimental corneal neovaseularization. Aeta Ophthalmol Seand,1999, 77:386-390.
8Duenas Z, Tomer L, Corbacho AM, et al. Inhibition of rat corneal angiogenesis by 16 - kDa prolactin and by endogenous prolactin - like molecules. Invest Ophthalmol Vis Sci, 1999, 40 (11): 2498-2505.
9Kenyon B M, Browne F, D'Amato R J. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization.Exp Eye Res, 1997, 64:971-978.
10Dana M R, Zhu S N, Yamada J. Topical modulation of interleukin-1 activity in corneal neovascularization. Cornea, 1998, 17:403 -409.
